Liver cancer is one of the leading causes of cancer deaths worldwide. Among all primary liver cancers, hepatocellular carcinoma (HCC) is the most common type, representing 75%-85% of all primary liver cancer cases. Median survival following diagnosis of HCC is approximately 6 to 20 months due to late diagnosis in its course and few effective treatment options. Interventional therapy with minimal invasiveness is recognized as a promising treatment for HCC. However, due to the heterogeneity of HCC and the complexity of the tumor microenvironment, the long-term efficacy of treatment for HCC remains a challenge in the clinic. Tumor microenvironment, including factors such as hypoxia, angiogenesis, low extracellular pH, interstitial fluid pressure, aerobic glycolysis, and various immune responses, has emerged as a key contributor to tumor residual and progression after locoregional treatment for HCC. New approaches to noninvasively assess the treatment response and assist in the clinical decision-making process are therefore urgently needed. Molecular imaging tools enabling such an assessment may significantly advance clinical practice by allowing real-time optimization of treatment protocols for the individual patient. This review discusses recent advances in the application of molecular imaging technologies for noninvasively assessing changes occurring in the microenvironment of HCC after locoregional treatment. (Hepatology Communications 2022;6:652-664).
(BCLC stage 0), early (BCLC stage A), intermediate stages (BCLC stage B), and even advanced stage (BCLC stage C). (3–5) However, increasing evidence indicates that changes in the tumor microenvironment (TME) of HCC after LRT may stimulate tumor proliferation, angiogenesis, treatment resistance, tumor recurrence, and metastasis, which limit the long-term efficacy of LRT. (6–11) Therefore, effectively monitoring the changes of TME in real time is particularly important for optimizing the strategy of LRT for HCC.

Although a few invasive approaches, such as oxygen electrodes (8) and microvessel density (MVD), (12) are available to monitor TME in HCC, most invasive methods may induce or accelerate tumor metastasis. Thus, the noninvasive methods that can be used to access the changes of TME in HCC are favorable and of great significance. Molecular imaging as an emerging technology enables the noninvasive visualization, characterization, and quantification of molecular events in living subjects. (13–15) The commonly used molecular imaging modalities include (1) positron emission tomography (PET) and single-photon emission computed tomography (SPECT); (2) magnetic resonance imaging (MRI); (3) optical imaging (OI), such as bioluminescence imaging and fluorescence imaging (FLI); and (4) contrast-enhanced ultrasound (US) and photoacoustic imaging (PAI) (Table 1). With the development of molecular imaging techniques, hybrid imaging modalities, such as PET/CT and PET/MRI, are proving to be invaluable, as they can provide comprehensive anatomic and functional information by taking the strengths of modalities.

In this review, we summarize the recent applications of molecular imaging to assess the TME in HCC post-locoregional therapy. Comments and future perspectives on the development of imaging techniques in this field are also provided.

Characterization of TME After LRT in HCC

The TME of HCC is a highly heterogeneous ecosystem composed of noncellular and cellular components, and it plays a key role in regulating liver fibrosis, liver cancer, epithelial–mesenchymal transition (EMT), tumor invasion, and metastasis. (6,16) The noncellular components of tumor stroma are usually characterized by extracellular matrix proteins, proteolytic enzymes, growth factors, and inflammatory cytokines, regulating HCC biology by influencing tumor signaling pathways in tumor cells. The cellular components consist primarily of, for example, HCC cells, HCC-related fibroblasts, immune cells, and endothelial cells. The interaction between tumor and stroma plays an active role in the recruitment and metabolic reprogramming of stromal cells in TME. (17–20)

Changes in the TME after LRT of HCC are often characterized by hypoxia, tumor angiogenesis,
up-regulation of glycolysis, low extracellular pH (pHe), increased interstitial fluid pressure, and various immune response, such as immune stimulation, immune suppression, and immune evasion, which is usually associated with tumor residue, recurrence, metastasis, and treatment resistance.\(^\text{[11,21,22]}\) TACE and RFA can expose residual cancer cells to a hypoxic TME.\(^\text{[7,10]}\) Detrimental effects of hypoxia in carcinogenesis include (1) induction of a more aggressive tumor phenotype (up-regulation of growth factors, induction of apoptosis resistance, DNA hypermethylation of tumor suppressor genes, and induction of EMT); (2) increased expression of immune checkpoints and impaired antitumor immune response, such
## Table 1. Major Molecular Imaging Modalities

| Imaging Modality | Detection | Spatial Resolution | Temporal Resolution | Advantages | Disadvantages | Application |
|------------------|-----------|--------------------|---------------------|------------|---------------|-------------|
| PET              | γ-ray     | 1-2 mm (microPET); 6-10 mm (clinical PET) | Second to minutes | High sensitivity; quantitative whole-body scanning; no tissue penetrating limit | Radiation risk; high cost; low spatial resolution | Functional imaging |
| SPECT            | γ-ray     | 0.5-2 mm (microSPECT); 7-15 mm (clinical SPECT) | Minutes | High sensitivity; no tissue penetrating limit | Radiation risk; low spatial resolution | Functional imaging |
| MRI              | Magnetic field | 0.01-0.1 mm (small-animal MRI); 0.5-1.5 mm (clinical MRI) | Minutes to hours | High spatial resolution; no tissue penetrating limit; no radiation risk | Relatively low sensitivity; long imaging time; exogenous contrast agent; low edge contrast | Anatomical/functional imaging |
| Fluorescence imaging | Fluorescence | 2-3 mm | Second to minutes | High sensitivity; multiplexed imaging | Low spatial resolution; poor tissue penetration; high degree of scattering | Functional imaging |
| Bioluminescence imaging | Fluorescence | 3-5 mm | Second to minutes | High sensitivity; high throughput | Relying on luciferin; requiring excitation (external light source); low potential for clinical translation | Functional imaging |
| US               | Ultrasonic waves | 0.01-0.1 mm for superficial (few mm depth) applications; 1-2 mm for deeper (few cm depth) applications | Second to minutes | Real time; low cost; portable | Low resolution; operator-dependent analysis | Anatomical/functional imaging |
| PAI              | Ultrasonic waves | ~0.01 to 1 mm | Second to minutes | Higher resolution (from optical tomography); deeper penetration (from ultrasonography); high optical contrast; low acoustic scattering | Shielding by strongly absorbing objects | Anatomical/functional imaging |
as impaired entry of antitumor immune cells, recruitment of immunosuppressive regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs); (3) stimulation of angiogenesis; (4) up-regulation of glycolysis; (5) low pH; and (6) increased interstitial fluid pressure (IFP). In addition, changes in the immune response are often observed in patients with HCC after LRT. LRT, including but not limited to TACE, MWA, RFA and Yttrium-90 (Y90), can cause various immune responses (23) (Fig. 1). It is worthwhile to mention that the TME change could be treatment-specific. For example, the main therapeutic effect of TACE is via ischemic tumor necrosis due to the embolic effect, while local ablation provides treatment via thermal damage to cancer. In addition, Y90 has no embolic or thermal effect but radiation can induce tumor necrosis with slower therapeutic effect than TACE or ablation. Various molecular imaging techniques are being developed for accessing the changes of TME in HCC (Table 2).

### Molecular Imaging of TME After LRT in HCC

#### HYPOXIA

Hypoxia can be assessed by hypoxia markers using molecular imaging modalities, such as PET,
MRI, OI, and PAI. Nitroreductase (NTR), hypoxia-inducible factor 1 alpha (HIF-1α), and carbonic anhydrase IX (CA-IX) are the major targets used for noninvasive imaging of tumor hypoxia. A variety of NTR-targeted radionuclide-labeled imaging agents, such as 18F-FMISO,\(^{(24)}\) 124I-IAZG,\(^{(24,25)}\) 18F-EF1\(^{(26)}\) and 18F-EF5\(^{(27)}\) have been developed for detecting the hypoxia region of HCC using PET imaging. The development of new oxygen-sensitive MRI techniques makes it possible to noninvasively detect the perfusion and oxygenation state of tumors.\(^{(8,17,28,29)}\) For example, blood oxygen level–dependent (BOLD) and tissue oxygen level–dependent MRI have been used in preclinical and clinical studies to assess the blood supply and oxygenation of HCC.\(^{(28,29)}\) The apparent diffusion coefficient in diffusion-weighted MRI (DW-MRI) and volume transfer constant (Ktrans), area under the curve (AUC) in dynamic contrast-enhanced MRI (DCE-MRI) are related to hypoxia markers, such as HIF-1α, CA-IX, and vascular endothelial growth factor (VEGF). Therefore, DW-MRI and DCE-MRI have been used to assess cell proliferation and hypoxia in HCC.\(^{(30,31)}\) In addition, NTR-targeted fluorescent probes, such as \(n\)-butyl benzyl phthalate,\(^{(32)}\) have shown the potential of detecting hypoxia of HCC by OI. A recent study demonstrated that PAI is useful for noninvasive monitoring of the changes of tissue oxygen saturation in a rodent model of HCC treated with sorafenib.\(^{(33)}\)

**ANGIOGENESIS**

Several targets of tumor angiogenesis, such as integrin \(\alpha_\beta_3\) and VEGF, are being intensively investigated to evaluate tumor angiogenesis in HCC by molecular imaging. For instance, the radiolabeled tracers, \(^{64}\)Cu-cyclam-RAFT-c(-RGDfK-)\(_4\))\(^{(34)}\) and \(^{99m}\)Tc-3PRGD\(_2\))\(^{(35)}\) were studied for monitoring integrin \(\alpha_\beta_3\) by PET and SPECT, whereas \(^{99m}\)Tc-NGR\(^{(36)}\) was prepared for targeting CD13 by SPECT. The vascular MRI techniques can be generally divided into two groups: (1) direct detection of angiogenesis with extrinsic contrast agents, such as DCE-MRI and MRI with targeted agents; and (2) indirect detection of angiogenesis without contrast agents, such as arterial spin labeling (ASL) and BOLD-MRI.\(^{(37)}\) DCE-MRI was used to measure the enhancement of exogenous contrast. On the other hand, ASL-MRI, BOLD-MRI, and DW-MRI have been used to measure the enhancement of endogenous contrast.\(^{(37-39)}\) The quantitative parameter Ktrans and semi-quantitative parameter iAUC60 of DCE-MRI are related to MVD, which can noninvasively assess tumor angiogenesis in the VX2 liver tumor model after PEI.\(^{(40)}\) Additionally, the Arg-Gly-Asp (RGD)-modified T1-Fe\(_3\)O\(_4\) was used as a highly sensitive positive contrast agent targeting integrin \(\alpha_\beta_3\), and it can monitor angiogenesis of HCC by MRI.\(^{(41)}\) Iron oxide nanoparticles also showed the utility of detecting the local sorafenib delivery to HCC for targeted embolotherapy and visualizing the distribution of microspheres using MRI.\(^{(42)}\) Furthermore, integrins \(\alpha_\beta_3\) and VEGF-targeted microbubbles were successfully tested for noninvasive monitoring of tumor angiogenesis in HCC by US.\(^{(43,44)}\) Quantitative three-dimensional (3D) DCE-US is also feasible to detect angiogenesis in liver tumor models.\(^{(45)}\) A comparison study of contrast-enhanced US (CEUS) and DCE-MRI was performed in a rat model of HCC, and the result showed that DCE-MRI is more accurate than CEUS to evaluate the sorafenib-induced reduction in vascular permeability.\(^{(46)}\)

**LOW pHe**

Molecular imaging techniques are developed for monitoring low pHe, which is largely related to tumor growth, invasion, metastasis, and chemoresistance.\(^{(47-50)}\) For example, Pd nanosheet-based radiotracers, \(^{131}\)I-Pd-PEG and \(^{125}\)I-Pd-PEG, were developed for SPECT/CT imaging of HCC.\(^{(47)}\) The results showed that the tumor retention of the radiotracer correlates well with the acidic microenvironment. MRI has been used for monitoring pHe in HCC with success in preclinical studies.\(^{(48-50)}\) Biosensor imaging of redundant deviation in shifts–based pHe mapping can serve not only as a longitudinal monitoring tool for noninvasive imaging of pHe but also as a functional surrogate biomarker for metabolic changes induced by cTACE of HCC\(^{(48,49)}\) (Fig. 2). The pHe mapping of HCC was also achieved by using chemical exchange saturation transfer MRI.\(^{(50)}\) In terms of OI, a new near-infrared (NIR) fluorescence probe, DiIRB-S, was developed for monitoring pHe in HCC.\(^{(51)}\) The results showed that the probe can target the primary tumors with a high tumor-to-background signal ratio, and a good correlation can
be established between the metastatic potential and acidosis distribution pattern in the tumor.

**GLYCOLYSIS AND LACTATE**

Glycolysis is related to metabolic reprogramming caused by hypoxia in the TME, leading to the overproduction of pyruvate, lactate, and carbonic acids. Tumor glycolysis can typically be evaluated using \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG) PET.\(^{22,52,53}\) Based on PET/CT imaging, several metabolic parameters, including maximum and mean standardized uptake values, peak standardized uptake values, metabolic tumor volume, and total lesion glycolysis, can be calculated to evaluate glycolysis after IAT of HCC.\(^{22,54}\)

Recently, \(^{13}\)C magnetic resonance spectroscopic imaging (\(^{13}\)C-MRSI) of hyperpolarized \([1-^{13}\)C]pyruvate and its metabolites was developed to study energy metabolism by visualizing.\(^{53,55}\) One study that compared spectroscopic images with \(^{18}\)F-FDG PET for visualizing tumor metabolism in a rat model of HCC revealed that PET and \(^{13}\)C-MRSI can be used to visualize increased glycolysis flux in HCC malignant tissues.\(^{53}\) Although the hyperpolarized \(^{13}\)C-MRSI of \([1-^{13}\)C]pyruvate increases the sensitivity of MRI, signal-to-noise ratio constraints still apply for spatially and temporally resolved \(^{13}\)C-MRSI, suggesting the further needs for magnetic resonance (MR) methodologic development (Fig. 3). In addition, an echo-planar 3D \(^{13}\)C-MRSI compression-sensing sequence using hyperpolarized \(^{13}\)C-MRSI was used to rapidly assess and locate the production of lactic acid in precursors, such as \(^{13}\)C-labeled pyruvate or glucose, for imaging of HCC in a preclinical study.\(^{55}\) Tumor voxels exhibited dramatically elevated lactate/pyruvate ratios (Fig. 4). Although \(^{13}\)C-MRSI is very sensitive for imaging metabolic events, rapid signal decay has a limitation of its broad application.

**IFP**

Tumor IFP is a physiological parameter that has a predictive value for tumor aggressiveness, drug delivery, as well as response to treatment, such as radiotherapy...
and chemotherapy. Recent studies demonstrated that heterogeneous intratumoral accumulation of liposomes is associated with chaotic tumor microcirculation and elevated IFP. For example, DCE computed tomography (DCE-CT) and DCE-MRI have been used to monitor the IFP of HCC in preclinical studies. Although diffusion-weighted (DW) MRI has been applied for the characterization of the IFP in cervical carcinoma and melanoma, the utility of DW-MRI in HCC remains uncertain.

**TME contains a repertoire of immune cells, such as innate tumor-associated macrophages, tumor-associated neutrophils, mast cells, MDSCs, cancer-associated fibroblasts (CAFs), dendritic cells, natural killer cells, Treg cells, and tumor-infiltrating lymphocytes (TILs). It is well-known that immune cell recruitments, various immune responses, and metabolic reprogramming are involved in tumor development and spread.**

**IMMUNE RESPONSE**

A near-infrared fluorescence probe (IRDye800-AbOX40) was used for noninvasive imaging of OX40 expression on TILs, and it can predict the early response to immunotherapy of HCC. Radiomics has been used as a method to detect the TME of HCC to optimize treatment decisions for immunotherapy. For example, MRI-based immunoscore can be used to evaluate the density of CD3+ and CD8+ T cells, and contrast-enhanced CT-based Rad score was calculated to estimate tumor-infiltrating CD8+ T cells.

CAFs are instrumental in coordinating cellular and molecule in TME, including recombinant extracellular matrix, secreting extracellular matrix metalloproteinases (MMPs), mediating angiogenesis, and regulating the proliferation of tumor and immune cells and migration. The high expression of fibroblast activation protein (FAP) in CAFs has been used as an ideal target for diagnosis. 68Ga-fibroblast activation protein inhibitor (68Ga-FAPI) exhibits excellent target specificity and pharmacokinetics, and it can be used for clinical
noninvasive monitoring of CAFs by PET/CT imaging. Increasing evidence shows that $^{68}$Ga-FAPI PET/CT imaging is useful for clinical noninvasive detection of CAFs in the TME of HCC.$^{(63,64)}$ $^{68}$Ga-FAPI PET/CT should also be considered complementary for tumor entities known to perform poorly with $^{18}$F-FDG in HCC. MMPs are proteolytic enzymes that play a key role in the initiation and progression of tumors, and they are related to tumor invasion and metastasis. A dual-modality imaging nanoprobe (Gd-Au@IR820) formed by self-assembly of ultrasmall AuNPs modified with MMP-2 on the surface was used for dual-mode (MRI/FLI) real-time imaging-guided photodynamic/photothermal combination therapy for HCC.$^{(65)}$ In another study, NIR dye-labeled MMP was used as a molecular probe to successfully detect MMP of HCC using FLI.$^{(66)}$ RGD, MMP, and $^{18}$F-FDG were imaged on tumor-bearing mice using PET, CT, X-ray, and multi-wavelength OI modalities.$^{(66)}$ Image results revealed that each agent is bound to a specific disease target component.

**OTHER MOLECULAR TARGETS**

TACE with immunotherapies can exploit tumor-associated antigens that are exposed during tissue destruction and presented by antigen-presenting immune cells (APCs) to activate T-lymphocytes.$^{(67)}$
A study demonstrated that specific gadolinium-160-labeled anti-human leukocyte antigen–DR isotope antibodies (160Gd-HLA-DR antibodies) and superparamagnetic iron oxide nanoparticles (SPIONs) showed curvilinear peritumoral distribution on MRI scans in a VX2 rabbit liver tumor model, corresponding to APCs and iron deposits in macrophages, respectively. In addition, glypican-3 (GPC3) is a carcinoembryonic antigen that is an ideal target for anticancer immunotherapy against HCC. A study showed that patients with GPC3-expressing HCCs exhibited an increase in GPC3-specific cytotoxic T lymphocytes after RFA or TACE, whereas none of the patients did after surgical resection. Molecular probes for targeting GPC3 are actively being developed for PET and OI.

Conclusion and Perspectives

Cancer immunotherapy has undergone a rapid expansion in terms of the number of agents that confer a prognostic benefit by activating the immune system to mount a response against developing tumors. Recently, immunotherapy approaches that involve blocking the immune-suppressive cytotoxic T-lymphocyte-associated protein 4 or programmed cell death protein 1 have shown promising results. However, the distinction between hot, altered, and cold tumors relies on the cytotoxic T-cell landscape within a tumor. Monitoring of TME with thorough profiling can better analyze the complexity of the tumors and provide dynamic information about the complex network changes occurring in the TME to assist in clinical decisions. With the advent of immunotherapy for HCC, there is an increasing interest in understanding how immunotherapy may be best combined with locoregional therapies. Currently, a good number of phase 2 and 3 clinical trials are investigating the combined locoregional-immunotherapy, such as the combination of TACE and immunotherapy (NCT04268888, NCT04246177, NCT03778957, NCT03575806, NCT03572582, NCT03592706, NCT03397654, NCT02856815, NCT02568748, and NCT02487017); the combination of ablation and immunotherapy (NCT03383458); the combination of TACE, ablation, and immunotherapy (NCT03124498 and NCT02821754); and the combination of Y90 and immunotherapy (NCT02837029, NCT03380130, NCT03033446, and NCT03099564). As new treatment approaches are being developed, noninvasive assessment, in real time, of tumor response to treatment currently remains a major challenge. Imaging tools to assist in this clinical decision-making process, thus enabling treatment optimization for the individual patient, are therefore urgently needed.

Clinically, assessment of response to LRT includes the measurement of tumor size, tumor margins, tumor necrosis, and the detection of residual or recurring and new tumors. Advances in morphological imaging techniques, particularly MRI and CT, have improved the detection and staging of tumors, as well as the measurement of therapy response. Further improvement in the HCC patient management through imaging will be limited unless anatomical studies are augmented with an assessment of tumor biology and metabolism in vivo. Metabolic imaging can be an excellent supplementary method for evaluating the response of LRT in HCC. PET and SPECT imaging modalities have been used to monitor the response of locoregional therapy in HCC. Recently, a clinical trial showed that 18F-fluorocholine (18F-FCH) PET/CT can predict the outcome of early-stage HCC undergoing LRT. Compared with FDG, 18F-FCH is considered to be more sensitive in detecting HCC, especially for well-differentiated HCC.

Image-guided surgery can visually distinguish tumor cells from surrounding tissues in real time, thereby facilitating the complete removal of tumor lesions. Indocyanine green (ICG) is the most popular imaging agent used for image-guided surgery, and it has been approved by the U.S. Food and Drug Administration for surgical procedures. In addition to ICG, many fluorescent dyes, including Cy5.5, Cy7, IRdye800 CW, and quantum dots have been extensively studied. After the conjugation with tumor-specific ligands of biomarkers, such as matrix metalloproteinase and integrin αvβ3, the imaging probes can enhance intraoperative tumor-specific uptake. It is expected that imaging tools will continue to play an important role in the LRT of HCC, including surgical resection.

Due to the heterogeneity of HCC and the complexity of the TME, combinations of imaging techniques, as so-called “multimodality imaging,” are being designed to take the strengths of modalities while minimizing their limitations, which as a result may simultaneously provide comprehensive biological
information. Although recent preclinical data are quite promising in the assessment of treatment response in HCC, a huge effort remains required to accelerate the translation of new imaging techniques from bench to bedside. To foster the continued discovery and development of imaging techniques, strong collaborations among academia, industry, and government are pivotal. In the foreseeable future, it is expected that molecular imaging techniques will be extensively applied in clinical settings and thus pave the way toward personalized cancer medicine to improve the management of patients with HCC.

REFERENCES

1) Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.
2) Akinyemiju T, Abraha S, Ahmed M, Alam N, Almayenh YA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-1691.
3) Makary MS, Khandpur U, Cloyd JM, Munntz K, Dowell JD. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. Cancers (Basel) 2020;12:1914.
4) Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology 2021;73(Suppl 1):137-149.
5) Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-773.
6) Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med 2018;50:e416.
7) Liu K, Zhang X, Xu W, Chen J, Yu J, Gamble JR, et al. Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Clin Transl Gastroenterol 2017;8:e98.
8) Walsh JC, Lebedev A, Tsenov M, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal 2014;21:1516-1554.
9) Greten TF, Mauda-Havukku M, Heinrich B, Korany F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol 2019;70:999-1007.
10) Tong Y, Yang H, Xu X, Ruan J, Liang M, Wu J, et al. Effect of a hypoxic microenvironment after radiofrequency ablation on residual hepatocellular cell migration and invasion. Cancer Sci 2017;108:753-762.
11) Zhou C, Yao QJ, Zhang H, Guo X, Liu J, Shi Q, et al. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis. Sci Rep 2020;10:2964.
12) Li W, Qiao YY, Li Y, Lu L, Cui M. Monitoring of tumor vascular normalization: the key points from basic research to clinical application. Cancer Manag Res 2018;10:4163-4172.
13) Weber WA, Czermin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, et al. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med 2020;61:2638-2725.
14) Bouche M, Hsu JC, Dong YC, Kim J, Taing K, Cormode DP. Recent advances in molecular imaging with gold nanoparticles. Bioconjug Chem 2020;31:303-314.
15) Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 2011;38:70-86.
16) Ibrahim AA, Schmithals C, Kowarz E, Koberle V, Kakoschky B, Pleti T, et al. Hypoxia causes downregulation of dicer in hepatocellular carcinoma, which is required for upregulation of hypoxia-inducible factor 1 alpha and epithelial-mesenchymal transition. Clin Cancer Res 2017;23:3896-3905.
17) Ramamonjisoa N, Ackerstaff E. Characterization of the tumor microenvironment and tumor-stroma interaction by non-invasive preclinical imaging. Front Oncol 2017;7:3.
18) Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011;21:35-43.
19) Hernandez-Geva V, Toffanin S, Friedman SL, Lloyd JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013;144:512-527.
20) Giannelli G, Rani B, Dittiri F, Cao Y, Palasciano G. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014;63:1668-1676.
21) Zhou D-Y, Qin J, Huang J, Wang F, Xu G-P, Ly V-T, et al. Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transarterial chemoembolization in rat hepatocellular carcinoma models. Oncol Lett 2017;14:4078-4084.
22) Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for monitoring response to embolotherapy (transarterial chemoembolization) in primary and metastatic liver tumors. PET Clin 2019;14:437-445.
23) Chang X, Lu X, Guo J, Teng GJ. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treat Rev 2019;74:49-60.
24) Riedl CC, Bradar P, Zanconzio P, Reid V, Woo Y, Wen B, et al. Tumor hypoxia imaging in orthotopic liver tumors and periportal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 2008;35:39-46.
25) Riedl CC, Bradar P, Zanconzio PB, Chus YS, Yoo W, Singh P, et al. Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiation 2008;248:561-570.
26) Evans SM, Chachur AV, Shiu CY, Hustins R, Jenkins WT, Shive GG, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF5. J Nucl Med 2000;41:327-336.
27) Ziener L, Evans S, Chachur A, Shuman A, Cardi C, Jenkins W, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole [18F]EF5. Eur J Nucl Med Mol Imaging 2003;30:259-266.
28) Bane O, Besser C, Wagner M, Oesingmann N, Zhu H, Fiel MI, et al. Feasibility and reproducibility of BOLD and TOLD measurements in the liver with oxygen and carbogen gas challenge in healthy volunteers and patients with hepatocellular carcinoma. J Magn Reson Imaging 2016;43:866-876.
29) Patterson AJ, Priest AN, Bowden DJ, Wallace TE, Patterson I, Graves MJ, et al. Quantitative BOLD imaging at 3T: temporal changes in hepatocellular carcinoma and fibrosis following oxygen challenge. J Magn Reson Imaging 2016;44:739-744.
30) Huang Z, Xu X, Meng X, Hou Z, Liu F, Hua Q, et al. Correlations between ADC values and molecular markers of...
magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma. Magn Reson Imaging 2019;57:156-164.

47) Chen M, Guo Z, Chen Q, Wei J, Li J, Shi C, et al. Pd nanosheets with their surface coordinated by radioactive iodide as a high-performance theranostic nanoagent for orthotopic hepatocellular carcinoma imaging and cancer therapy. Chem Sci 2018;9:4268-4274.

48) Savic LJ, Schobert IT, Peters D, Walsh JJ, Laage-Gaupp FM, Hamm CA, et al. Molecular imaging of extracellular tumor pH to reveal effects of locoregional therapy on liver cancer microenvironment. Clin Cancer Res 2020;26:428-438.

49) Conlan D, Peters DC, Walsh JJ, Savic LJ, Huber S, Sinussas AJ, et al. Extracellular pH mapping of liver cancer on a clinical 3T MRI scanner. Magn Reson Med 2020;83:1553-1564.

50) Chen M, Chen C, Shen Z, Zhang X, Chen Y, Lin F, et al. Extracellular pH is a biomarker enabling detection of breast cancer and liver cancer using CEST MRI. Oncotarget 2017;8:45759-45767.

51) Wang L, Fan Z, Zhang J, Changyi Y, Huang C, Gu Y, et al. Evaluating tumor metastatic potential by imaging intratumoral acidosis via pH-activatable near-infrared fluorescent probe. Int J Cancer 2015;136:E107-E116.

52) Zhang LF, Lou JT, Lu MH, Gao C, Zhao S, Li B, et al. Suppression of miR-199a maturation by HUr is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. EMBO J 2015;34:2671-2685.

53) Mentzel MI, Farrell EV, Janich MA, Khegai O, Wiesinger F, Nekolla S, et al. Multimodal assessment of in vivo metabolism with hyperpolarized [1-13C]MR spectroscopy and 18F-FDG PET imaging in hepatocellular carcinoma tumor-bearing rats. J Nucl Med 2013;54:1113-1119.

54) Sager S, Akgün E, Uslu-Beşli L, Asa S, Akovali B, Sahin O, et al. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma. Nucl Med Commun 2019;40:461-468.

55) Hu S, Lustig M, Balakrishnan A, Larson PE, Bok R, Kurhanewicz J, et al. 3D compressed sensing for highly accelerated hyperpolarized 13C MRI with in vivo applications to transgenic mouse models of cancer. Magn Reson Med 2010;63:312-321.

56) Stapleton S, Miloševic M, Allen C, Zheng J, Dunne M, Yeung I, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One 2013;8:e81157.

57) Liu LJ, Brown SL, Ewing JR, Ala BD, Schneider KM, Schlesinger M. Estimation of tumor interstitial fluid pressure (TIFP) noninvasively. PLoS One 2016;11:e0140892.

58) Hompland T, Ellingsen C, Galapathi K, Rofstad EK. Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI. Acta Oncol 2014;53:6-15.

59) Hompland T, Ellingsen C, Galapathi K, Rofstad EK. DW-MRI in assessment of the hypoxic fraction, interstitial fluid pressure, and metastatic propensity of melanoma xenografts. BMC Cancer 2014;14:92.

60) Chen X, Li D, Cao Y, Gao J, Jin H, Shan H. Early therapeutic vaccination prediction of hepatocellular carcinoma via imaging OX40-mediated tumor infiltrating lymphocytes. Mol Pharm 2019;16:4252-4259.

61) Chen S, Feng S, Wei J, Liu F, Li B, Li X, et al. Pretreatment prediction of immunocore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019;29:4177-4187.

62) Liao H, Zhang Z, Chen J, Liao M, Xu L, Wu Z, et al. Preoperative radiomic approach to evaluate tumor-infiltrating CD8+ T cells in...
hepatocellular carcinoma patients using contrast-enhanced computed tomography. Ann Surg Oncol 2019;26:4537–4547.

63) Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Lekotek A, Lehnerd W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 2019;60:386–392.

64) Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [18F]florbetapir PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 2020;47:1820–1832.

65) Li B, Sun L, Li T, Zhang Y, Niu X, Xie M, et al. Ultra-small gold nanoparticles self-assembled by gadolinium ions for enhanced photothermal/photodynamic liver cancer therapy. J Mater Chem B 2021;9:1138–1150.

66) Ke S, Zhang F, Wang W, Qiu X, Lin J, Cameron AG, et al. Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model. Curr Mol Med 2012;12:944–951.

67) Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma Y, Savic LJ, Doemel LA, Schobert IT, Montgomery RR, Joshi N, et al. Identification of a glypican-3-binding peptide for PET imaging of hepatocellular carcinoma. Hepatology 2013;57:1448–1457.

68) Sham JG, Kievit FM, Grierson JR, Miyaoaka RS, Yeh MM, Zhang N. Baseline and post-treatment 18F-Fluorocholine PET/CT to locoregional and systemic therapy. AJR Am J Roentgenol 2013;201:80–96.

69) Gonzalez-Guindalini FD, Botelho MPF, Harmath CB, Sandrasegaran K, Miller FH, Salem R, et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 2013;33:1781–1800.

70) Talbott J-N, Gutman F, Fouloux L, Grange J-D, Ganne N, Kersou K, et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285–1289.

71) Wang C, Wang Z, Zhao T, Li Y, Huang G, Sumer BD, et al. Optical molecular imaging for tumor detection and image-guided surgery. Biomaterials 2018;157:62–75.

72) Chi C, Du Y, Ye J, Kou D, Qiu J, Wang J, et al. Intraperioperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics 2014;4:1072–1084.

73) Zhao Z, Jiang D, Zhang Y, Yu J, Huang S, Conti PS, et al. Radiofluorinated GPC3-binding peptides for PET imaging of hepatocellular carcinoma. Mol Imaging Biol 2020;22:134–143.

74) Wu M, Jiang D, Mu S, Liang S, Liu Y, Zhang N. Promoting early diagnosis and precise therapy of hepatocellular carcinoma by gypican-3-targeted synergistic chemo-photothermal theranostics. ACS Appl Mater Interfaces 2019;11:23591–23604.

75) Qin Z, Wang J, Wang YE, Wang G, Wang X, Zhou Z, et al. Identification of a gypican-3-binding peptide for in vivo non-invasive human hepatocellular carcinoma detection. Macromol Biosci 2017;17:1600335.

76) Singh P, Toom S, Avula A, Kumar V, Rahma OE. The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma 2020;7:11–17.

77) Yaghmai V, Besa C, Kim E, Garlin JL, Siddiqui NA, Taouli B. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 2013;201:80–96.

78) Gonzalez-Guindalini FD, Botelho MPF, Harmath CB, Sandrasegaran K, Miller FH, Salem R, et al. Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 2013;33:1781–1800.

79) Dierckx R, Maes A, Peeters M, Van De Wiele C. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging 2009;53:336–342.

80) Wallace MC, Sek K, Francis RJ, Samuelson J, Tibballs J, et al. Baseline and post-treatment 18F-Fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapy. Dig Dis Sci 2020;65:647–657.

81) Talbott J-N, Gutman F, Fouloux L, Grange J-D, Ganne N, Kersou K, et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285–1289.

82) Wang C, Wang Z, Zhao T, Li Y, Huang G, Sumer BD, et al. Optical molecular imaging for tumor detection and image-guided surgery. Biomaterials 2018;157:62–75.

83) Chi C, Du Y, Ye J, Kou D, Qiu J, Wang J, et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics 2014;4:1072–1084.

84) Goltiz M, Majlesara A, El Sakka S, Ashrafi M, Arwin J, Fard N, et al. Small for size and flow (SFSF) syndrome: an alternative description for posthepatectomy liver failure. Clin Res Hepatol Gastroenterol 2016;40:267–275.

85) Fan Z, Zong J, Lau WY, Zhang Y. Indocyanine green and its nanosynthetic particles for the diagnosis and treatment of hepatocellular carcinoma. Am J Transl Res 2020;12:2344–2352.

86) Wang Y, Stewart E, Desjardins L, Hadwaj J, Morrison L, Cruklecy C, et al. Assessment of intratumor hypoxia by integrated 18F-FDG PET/perfusion CT in a liver tumor model. PLoS One 2017;12:e0173016.

87) Stapleton S, Milosevic M, Tannock IF, Allen C, Jaffray DA. The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. J Control Release 2015;211:163–170.

Author names in bold designate shared co-first authorship.